OBJECTIVES: We sought to describe the effect of a @entity1534 eradication strategy on health care costs among a cohort of health maintenance organization (HMO) members with @entity10189 ( @entity10189 ). METHODS: @entity1 were identified from an outpatient diagnosis database and verified at chart review to have new-onset @entity10189 by @entity1729 or upper gastrointestinal radiographic series. Health plan registration and accounting databases were used to track costs over 12 months after initial diagnosis. Costs were analyzed separately for an initial 2-month interval and a 10-month follow-up period. Inpatient and pharmacy costs are those directly attributable to @entity10189 (either a @entity10189 -related discharge diagnosis or an antiulcer medication prescription). Outpatient costs are total costs. All cost differences were adjusted for age and gender. RESULTS: Twenty-seven of 93 @entity1 meeting selection criteria received @entity1534 treatment. During the 2-month treatment window, adjusted @entity10189 -related inpatient costs were higher for the @entity1534 treated group (difference,  234.00/ @entity1 ), whereas total outpatient costs and @entity10189 -related pharmacy costs were similar. During the 10-month follow-up period, @entity10189 -related inpatient and pharmacy adjusted costs were similar, but adjusted outpatient costs in the @entity1534 treated group were lower than in the untreated group (difference,  508.00/ @entity1 ). Total adjusted follow-up period costs were  555.00/ @entity1 less in the @entity1534 treated group (p = 0.05). Total 12-month costs in the @entity1534 treated group were  285.00/per @entity1 less than in untreated @entity1 , (p > 0.2); 30% of @entity1534 treated @entity1 were still receiving antisecretory therapy 1 yr after diagnosis, compared to 41.9% of untreated @entity1 . CONCLUSIONS: @entity1534 treatment is associated with a decreased cost of follow-up care for @entity1 with @entity10189 , primarily due to decreased outpatient utilization.

A cost analysis of a XXXX eradication strategy in a large health maintenance organization.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'person'] @entity10189 :: ('MESH:D010437', 'Disease') :: ['peptic ulcer disease', 'PUD'] @entity1729 :: ('MESH:D012141', 'Disease') :: ['upper endoscopy'] @entity1534 :: ('210', 'Species') :: ['H. pylori', 'Helicobacter pylori']
@entity1534 :: (210,Species) :: ['Helicobacter pylori']
